Status:
COMPLETED
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Lead Sponsor:
Shandong Cancer Hospital and Institute
Conditions:
Malignancies
Stomach Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies. Integrin αvβ3 has been...
Detailed Description
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 positron emission tomography/computed tomography (18F-RGD PET/CT) scan can predict the efficacy and adverse events of apat...
Eligibility Criteria
Inclusion
- Clinical diagnosis of malignancies
- Scheduled for second- or third-line apatinib therapy
- Karnofsky performance status (KPS) ≥70
- Measurable primary tumors according to Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion
- Active infection, myocardial infarction within 6 months, symptoms of heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy
- The claustrophobic patients and patients with implanted metal objects
- The pregnancy
- Inability to complete the required examinations
Key Trial Info
Start Date :
September 30 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2018
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03384511
Start Date
September 30 2016
End Date
January 28 2018
Last Update
February 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinan, Shandong, China, 250117